Hannover Rück Valuation
Is HNR1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of HNR1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: HNR1 (€225.2) wird unter unserer Schätzung des Fair Value (€442.65) gehandelt.
Deutlich unter dem Marktwert: HNR1 wird um mehr als 20 % unter dem Marktwert gehandelt.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HNR1?
Other financial metrics that can be useful for relative valuation.
| What is HNR1's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | €28.91b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.3x |
| Enterprise Value/EBITDA | 14x |
| PEG Ratio | 1.6x |
Price to Earnings Ratio vs Peers
How does HNR1's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 7.3x | ||
VIG Vienna Insurance Group | 5.7x | n/a | €3.7b |
UQA UNIQA Insurance Group | 5.8x | n/a | €2.5b |
SREN Swiss Re | 10.9x | 7.4% | CHF31.5b |
EG Everest Group | 6.6x | 10.6% | US$16.5b |
HNR1 Hannover Rück | 15.8x | 9.8% | €28.9b |
Price-To-Earnings gegen Gleichaltrige: HNR1 ist auf der Grundlage des Price-To-Earnings Verhältnisses (16.1x) im Vergleich zum Durchschnitt der Vergleichsgruppe (7.2x) teuer.
Price to Earnings Ratio vs Industry
How does HNR1's PE Ratio compare vs other companies in the European Insurance Industry?
Price-To-Earnings gegen Industrie: HNR1 ist teuer, wenn man sein Price-To-Earnings Verhältnis (16.1x) mit dem European Insurance Branchendurchschnitt (10.9x) vergleicht.
Price to Earnings Ratio vs Fair Ratio
What is HNR1's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 15.8x |
| Fair PE Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Earnings Fair Ratio von HNR1 für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €238.80 | €238.40 -0.2% | 14.4% | €290.00 | €160.00 | n/a | 15 |
| Mar ’25 | €236.80 | €220.17 -7.0% | 11.6% | €260.00 | €160.00 | n/a | 16 |
| Feb ’25 | €220.00 | €219.23 -0.3% | 11.3% | €255.00 | €160.00 | n/a | 16 |
| Jan ’25 | €215.20 | €213.79 -0.7% | 11.8% | €255.00 | €160.00 | n/a | 16 |
| Dec ’24 | €219.30 | €209.85 -4.3% | 11.9% | €255.00 | €160.00 | n/a | 16 |
| Nov ’24 | €214.60 | €200.03 -6.8% | 12.1% | €255.00 | €145.00 | n/a | 16 |
| Oct ’24 | €207.90 | €198.78 -4.4% | 11.7% | €255.00 | €145.00 | n/a | 16 |
| Sep ’24 | €196.15 | €197.40 +0.6% | 10.8% | €240.00 | €145.00 | n/a | 16 |
| Aug ’24 | €193.55 | €192.96 -0.3% | 10.9% | €235.00 | €145.00 | n/a | 15 |
| Jul ’24 | €194.70 | €193.54 -0.6% | 9.9% | €220.00 | €145.00 | n/a | 17 |
| Jun ’24 | €205.60 | €191.18 -7.0% | 9.5% | €220.00 | €145.00 | n/a | 17 |
| May ’24 | €193.55 | €190.12 -1.8% | 9.6% | €220.00 | €145.00 | n/a | 17 |
| Apr ’24 | €180.80 | €189.74 +4.9% | 9.8% | €220.00 | €145.00 | €254.10 | 17 |
| Mar ’24 | €183.70 | €190.93 +3.9% | 10.6% | €220.00 | €145.00 | €236.80 | 17 |
| Feb ’24 | €180.40 | €192.16 +6.5% | 10.7% | €225.00 | €145.00 | €220.00 | 17 |
| Jan ’24 | €186.10 | €183.14 -1.6% | 11.6% | €210.00 | €131.00 | €215.20 | 17 |
| Dec ’23 | €182.55 | €178.91 -2.0% | 11.2% | €210.00 | €131.00 | €219.30 | 17 |
| Nov ’23 | €165.30 | €169.17 +2.3% | 10.4% | €195.00 | €131.00 | €214.60 | 18 |
| Oct ’23 | €153.80 | €168.43 +9.5% | 11.4% | €205.00 | €121.00 | €207.90 | 18 |
| Sep ’23 | €147.20 | €167.51 +13.8% | 11.3% | €205.00 | €121.00 | €196.15 | 18 |
| Aug ’23 | €137.45 | €169.04 +23.0% | 9.1% | €195.00 | €138.20 | €193.55 | 17 |
| Jul ’23 | €140.55 | €170.84 +21.5% | 10.3% | €205.00 | €144.00 | €194.70 | 16 |
| Jun ’23 | €138.50 | €171.73 +24.0% | 11.5% | €215.00 | €144.00 | €205.60 | 17 |
| May ’23 | €148.95 | €168.83 +13.3% | 13.8% | €215.00 | €116.00 | €193.55 | 18 |
| Apr ’23 | €152.60 | €172.54 +13.1% | 14.2% | €220.00 | €116.00 | €180.80 | 18 |
Analysten-Prognose: Das Kursziel ist niedriger als der aktuelle Aktienkurs.